Highlights

I think AD is sort of undergoing a revolution at the moment and for a long time we haven’t had any new therapies but suddenly there’s lots of them, either have come into clinical practice or are imminently about to come into clinical practice. So I think that the more severe population is now getting some options. I think that, however, it is a very heterogeneous disease and actually, when we look at the data of the drugs that are coming through, they don’t work for everybody. Some of the JAK kinase inhibitors are more impressive than perhaps biologics, but the JAK kinase inhibitors come with potential safety issues. So the severe population has a lot more options, either now or imminently. Some of the options are good, but there will remain 50% who are still not particularly well treated. Then I would argue that because in health economics-driven places like the UK, because many of the drugs are coming with stipulations of who can
have them based on severity and so, it means that people with anything less than that severity can’t necessarily access those treatments and I think that remains hugely problematic because there’s still a massive burden of disease for which there’s no new therapies and people are still going to topical corticosteroids